首页 | 本学科首页   官方微博 | 高级检索  
     

胆管癌代谢组学研究进展
引用本文:何永平,焦杨,刘悦. 胆管癌代谢组学研究进展[J]. 药学实践杂志, 2023, 41(12): 705-709,732
作者姓名:何永平  焦杨  刘悦
作者单位:海军军医大学药学系药物分析教研室, 上海 200433;广西医科大学药学院, 广西 南宁 530021;崇左市人民医院药学部, 广西 崇左 532200;海军军医大学药学系药物分析教研室, 上海 200433;上海市药物(中药)代谢产物研究重点实验室, 上海 200433
基金项目:上海市科学技术委员会“启明星”项目(21QA 1411600)
摘    要:胆管癌(CCA)恶性程度高,由于早期缺乏典型症状且尚无准确的生物标志物,发现时常处于晚期,预后较差。胆管癌的发生发展与代谢密切相关,代谢组学是研究在病理生理或基因修饰等因素影响下,生物体内内源性小分子代谢物变化的学科,具有全局分析、高通量和反映生物体系实时变化的特点,可以为胆管癌生物标志物的筛选、疾病诊疗提供新途径。综述近年来代谢组学在胆管癌方面的研究进展,以期为进一步研究提供参考。

关 键 词:胆管癌  代谢组学  生物标志物  发病机制  早期诊断  药效评价
收稿时间:2022-11-09
修稿时间:2023-04-28

Advances in metabolomics of cholangiocarcinoma
HE Yongping,JIAO Yang,LIU Yue. Advances in metabolomics of cholangiocarcinoma[J]. The Journal of Pharmaceutical Practice, 2023, 41(12): 705-709,732
Authors:HE Yongping  JIAO Yang  LIU Yue
Affiliation:Department of Pharmaceutical Analysis, School of Pharmacy, Naval Medical University, Shanghai 200433, China;School of Pharmacy, Guangxi Medical University, Nanning 530021, China;Department of Pharmacy, the People''s Hospital of Chongzuo, Chongzuo 532200, China; Department of Pharmaceutical Analysis, School of Pharmacy, Naval Medical University, Shanghai 200433, China;Shanghai Key Laboratory for Pharmaceutical Metabolite Research, Shanghai 200433, China
Abstract:As a highly malignant tumor, the diagnosis of cholangiocarcinoma (CCA) is often late and the prognosis is poor for which the early symptoms are atypical and the lack of accurate biomarkers. Metabolomics is an emerging science that researches the alterations of all endogenous small molecule metabolites in an organism under the influence of pathological, physiological or genetic modification. The development and progress of CCA is closely related to metabolism. Metabolomic is characterized by global analysis, high throughput and reflects real-time alterations in biology system, providing a new avenue for biomarker screening and diseases diagnosis and treatment. The advances of metabolomics studies on CCA in the recent years were reviewed in this paper which could provide the reference for further research.
Keywords:cholangiocarcinoma  metabolomic  biomarkers  mechanism  early diagnosis  pharmacodynamic evaluation
点击此处可从《药学实践杂志》浏览原始摘要信息
点击此处可从《药学实践杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号